Measurement of Autoantibodies Against Fibrinogen and Fibrin Degradation Products by Enzyme-Linked Immunoassay

Summary

We have devised a simple enzyme immunoassay to detect and quantitate autoantibodies against derivatives of fibrinogen. This assay has been applied with a range of antigens including a fibrinogen lysate (containing X, Y, D and E), D dimer, D dimerE and a preparation of high molecular weight complexes derived from crosslinked fibrin. We have found that autoantibodies interacting with these antigens can be detected in varying concentrations in most sera from both normal subjects and patients with a variety of diseases and are evidently of mixed Ig class. These autoantibodies are directed against at least several cryptic antigens which appear during fibrinogen/fibrin degradation and some appear to be directed specifically against cross- linked fibrin derivatives. No clear disease correlates have yet emerged but a relationship between elevated levels and prior infective, thrombotic, inflammatory or traumatic disorders is likely. It is suggested that these autoantibodies may contribute to the catabolism of fibrinogen derivatives, provide a marker of thrombosis, and sometimes produce pathologic effects.

Key words

Fibrin(ogen) degradation products - Autoimmunity - Intravascular coagulation - Enzyme-linked immunoassay

• References

• 1 Contreras CE, Orozco A, Sanchez P, Ortega G, Bianco NE. Physiological aspects of circulating immune complexes in the normal population. Clin Exp Immunol 1982; 48: 693-699
• 2 Plow EF, Edgington TS. Immune responses to the cleavage- associated neoantigens of fibrinogen in man. Identification and characterization of humoral antibodies specific for cleavage fragments J Clin Invest 1975; 56: 1509-1518
• 3 Mammen EF, Schmidt KP, Barnhart MI. Thrombophlebitis migrans associated with circulating antibodies against fibrinogen. Thrombos Diathes Haemorrh 1967; 18: 605-611
• 4 Hoots WK, Carrell NA, Wagner RH, Cooper HA, McDonagh J. A naturally occurring antibody that inhibits fibrin polymerization. N Engl J Med 1981; 304: 857-861
• 5 Ghosh S, McEvoy P, McVerry BA. Idiopathic autoantibody that inhibits fibrin monomer polymerization. Br J Haematol 1983; 53: 65-72
• 6 Plow EF, Edgington TS. Surface markers of fibrinogen and its physiologic derivatives revealed by antibody probes. Semin Thromb Haemostas 1982; 8: 36-56
• 7 Whitaker AN, Elms MJ, Masci PP, Bundesen PG, Rylatt DB, Webber AJ, Bunce IH. Measurement of crosslinked fibrin derivatives in plasma: An immunoassay using monoclonal antibodies. J Clin Pathol 1984; 37: 882-887
• 8 Elms MJ, Bunce IH, Bundesen PG, Rylatt DB, Webber AJ, Masci PP, Whitaker AN. Measurement of crosslinked fibrin degradation products - An immunoassay using monoclonal antibodies. Thromb Haemostas 1983; 50: 591-594
• 9 Rylatt DB, Blake AS, Cottis LE, Massingham DA, Fletcher WA, Masci PP, Whitaker AN, Elms M, Bunce I, Webber AJ, Wyatt D, Bundesen PG. An immunoassay for human D dimer using monoclonal antibodies. Thromb Res 1983; 31: 767-778
• 10 Cierniewski CS, Janiak A, Nowak P, Augustyniak W. Reactivity of fibrinogen derivatives with antisera to human fibrin D dimer and its γ-γ chain remnant. Thromb Haemostas 1982; 48: 33-37
• 11 Gaffney PJ. Molecular aspects of fibrinolysis. Ann NY Acad Sci 1981; 370: 551-567
• 12 Sobel JH, Koehn JA, Friedman R, Canfield RE. Alpha chain crosslinking of human fibrin: Purification and radioimmunoassay development for two Aα chain regions involved in crosslinking. Thromb Res 1982; 26: 411-424
• 13 Takagi K, Kawai T. Radioimmunoassay of an early plasmin degradation product of human fibrinogen, “fragment A”, and its clinical application. Thromb Haemostas 1978; 39: 1-11
• 14 Pacella Jr BL, Hui KY, Haber E, Matsueda GR. Induction of fibrin-specific antibodies by immunization with synthetic peptides that correspond to amino termini of thrombin cleavage sites. Mol Immunol 1983; 20: 521-527
• 15 Soria J, Soria C, Boucheix C, Mirshahi M, Perrot JY, Bernadou A, Samama M. Immunochemical differentiation of fibrinogen fragment D or and crosslinked fibrin degradation products using monoclonal antibodies. In “Fibrinogen - StructuresFunctional AspectsMetabolism”. Haverkate F, Henschen A, Nieuwenhuizen W, Straub PW. (Eds) Walter de Gruyter & Co; Berlin, New York: 1983. 2 227-233
• 16 Plow EF, Gramse M, Havemann K. Immunochemical discrimination of leukocyte elastase from plasmic degradation products of fibrinogen. J Lab Clin Med 1983; 102: 858-869
• 17 Deutsch DG, Mertz ET. Plasminogen: Purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1096
• 18 Robbins KC, Summaria L. Plasminogen and plasmin. Methods Enzymol 1976; 45 (Part B) 257-273
• 19 Saunders GC. The art of solid-phase immunoassay including selected protocols. In “Immunoassays in the Clinical Laboratory”. Nakamura RM, Dito WR, Tucker III ES, (Eds) Alan R. Liss Inc; New York: 1979. pp 99-118
• 20 Porstmann B, Porstmann T, Gaede D, Nugel E, Egger E. Temperature dependent rise in activity of horseradish peroxidase caused by non-ionic detergents and its use in enzyme-immunoassay. Clin Chim Acta 1981; 109: 175-181
• 21 Galanakis DK, Ginzler EM, Fikrig SM. Monoclonal IgG anticoagulants delaying fibrin aggregation in two patients with systemic lupus erythematosus. Blood 1978; 52: 1037-1046
• 22 DeVries A, Rosenberg T, Kochwa S, Boss J. Precipitating antifibrinogen antibody appearing after fibrinogen infusions in a patient with congenital afibrinogenemia. Am J Med 1961; 30: 486-494
• 23 Cheung K, O’Kane D, Robinson MF. Measurement of circulating immune complexes in human sera by enzyme immunoassay. Aust J Exp Biol Med Sci 1982; 60: 593-605
• 24 MacKenzie AR. Non-trypanosome specific components of the elevated IgM levels in rabbit trypanosomiasis. Trans R Soc Trop Med Hyg 1972; 66: 344-345
• 25 Boreham PF L, Facer CA. Autoimmunity in trypanosome infections. II. Anti-fibrin/fibrinogen (anti-F) autoantibody in Trypanosoma (Trypanozoon) brucei infections of the rabbit. Int J Parasitol 1974; 4: 601-607
• 26 Rickman WJ, Cox HW. Immunologic reactions associated with anaemia, thrombocytopenia, and coagulopathy in experimental African trypanosomiasis. J Parasitol 1980; 66: 28-33
• 27 Mahoney DF, Goodger BV. Serum changes in infected calves. Exp Parasitol 1969; 24: 375-382
• 28 Thoongsuwam S, Cox HW, Rickman WJ. Antibody to fibrinogen/ fibrin products (anti-F) in malaria, babesiosis, and trypanosomiasis of rodents. J Parasitol 1979; 65: 426-429
• 29 Sherman LA, Fletcher AP, Sherry S. In vivo transformation between fibrinogens of varying ethanol solubilities: a pathway of fibrinogen catabolism. J Lab Clin Med 1969; 73: 574-583
• 30 Galanakis DK, Mosesson MW. Human fibrinogen heterogeneities: determination of the major Act chain derivatives in blood. Thromb Res 1983; 31: 403-413
• 31 Kalowski S, Howes EL, Margaretten W, McKay DG. Effects of intravascular clotting on the activation of the complement system. Am J Pathol 1975; 78: 525-536
• 32 Gonzalo A, Mampaso F, Gallego N, Bellas C, Segui J, Ortuno J. Hemolytic uremic syndrome with hypocomplementemia and deposits of IgM and C3 in the involved renal tissue. Clin Nephrol 1981; 16: 193-199
• 33 Barre P, Kaplan BS, Chadarevian de J-P, Drummond KN. Hemolytic uremic syndrome with hypocomplementemia, serum C3NeF, and glomerular deposits of C3. Arch Pathol Lab Med 1977; 101: 357-361
• 34 Segonds A, Louradour N, Sue JM, Orfila C. Postpartum hemolytic uremic syndrome: A study of three cases with a review of the literature. Clin Nephrol 1979; 12: 229-242
• 35 Houwert-de Jong MH, te Velde ER, Nefkens MJ J, Schuurman HJ. Immune complexes in skin of patients with pre-eclamptic toxaemia. Lancet 1982; 2: 387
• 36 Crain SM, Choudhury AM. Thrombotic thrombocytopenic purpura: A reappraisal. JAMA 1981; 147: 1243-1246
• 37 Whitaker AN, Bunce IH, Sleigh B. Thrombosis, pulmonary embolism and coagulation inhibitors in systemic lupus erythematosus. IRCS Med Sci 1978; 6: 197
• 38 Wilner GD, Hsieh K-H, Thomas DW. Immunology of fibrinogen: Comparisons of serologic and cellular immune responses to human fibrinopeptide B (hFPB). Ann NY Acad Sci 1981; 370: 528-535